International Kidney Cancer Symposium | Conferences

Precision Medicine According to Histologic Subtype in Renal Cell Carcinoma

November 06, 2021

During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.

Safety, Antitumor Activity of Modified Ipilimumab/Nivolumab Regimen Reinforces Approved Dosing in RCC

November 07, 2020

Investigators of the CheckMate 920 trial found no differences in safety signals or responses with modified dosing of nivolumab and ipilimumab compared with the standard dose in patients with advanced renal cell carcinoma treated in the frontline.